ABSTRACT: The T-cell cytokine interleukin (IL)-17 selectively accumulates neutrophils in murine airways in vivo and may thus constitute a link between activation of T-lymphocytes and accumulation of neutrophils. In this study, the authors evaluated the role of granulocyte macrophage-colony stimulating factor (GM-CSF) in accumulation of neutrophils in the airways caused by IL-17 and tumour necrosis factor (TNF)-a.
The accumulation of neutrophilic granulocytes occurs in several types of inflammatory airway diseases, including chronic bronchitis, chronic obstructive pulmonary disease (COPD) and acute, severe bronchial asthma [1] [2] [3] . This accumulation of neutrophils may contribute to airway obstruction, hypersecretion and remodelling by releasing proteolytic enzymes and oxygen free radicals [4] [5] [6] [7] . Although the precise mechanisms behind this type of pathological accumulation of neutrophils are not fully understood, it seems that several cytokines controlling the production, recruitment, activation and survival of neutrophils are involved, either directly or indirectly [8] [9] [10] .
Interleukin (IL)-17 is a recently characterised cytokine that is produced primarily by activated T-lymphocytes of the CD4z and CD8z subsets [11] , cells that are involved in orchestrating various inflammatory responses [12, 13] . The receptor for IL-17 is widely distributed and it is expressed on bronchial epithelial and endothelial cells as well as on a wide range of cells in lung tissue [14] . It is known that IL-17 can induce the production of neutrophil-mobilising cytokines, such as IL-6, IL-8 and granulocyte-colony stimulating factor, and thus has the potential to induce neutrophil recruitment indirectly [15] . IL-17 is therefore considered to be a proinflammatory cytokine. However, despite studies demonstrating increased immunoreactivity for IL-17 in the airways of patients with asthma [16] and showing increased IL-17 protein levels in human airways during severe neutrophilic inflammation [17] , the pathogenetic importance of IL-17 in human airway disease remains to be confirmed.
The current authors recently demonstrated that human (h) and mouse (m) IL-17 cause a selective accumulation of neutrophils in rat airways without having any substantial effect on the accumulation of other inflammatory cell types [18] . The authors also demonstrated that hIL-17 exert its effect in the airways, in part, by releasing C-X-C chemokines [19] . This makes it feasible that IL-17 links the activation of its cellular source, the T-lymphocyte, to the accumulation of neutrophils in the airways indirectly, via induced release of neutrophil-mobilising cytokines. However, at present, it is not known whether IL-17 also causes accumulation of neutrophils in the airways by increasing the survival of neutrophils.
The cytokine granulocyte macrophage-colony stimulating factor (GM-CSF) is a growth factor that can regulate both the accumulation and the activity of neutrophils [19, 20] . GM-CSF can facilitate the recruitment of neutrophils to inflammatory sites by increasing the expression of adhesion molecules on these inflammatory cells [21] and by increasing the response of these cells to chemotactic stimuli [22] . In addition, GM-CSF can prolong the survival of neutrophils by inhibiting their apoptosis [23, 24] . In line with this, the local concentration of GM-CSF is increased in airway disease characterised by an accumulation of neutrophils [1, 25] . Factors that control the local release of GM-CSF may therefore indirectly modulate the accumulation of neutrophils.
The primary aim of the current study was to determine whether IL-17 per se or IL-17 with another pro-inflammmatory cytokine, tumour necrosis factor (TNF)-a, can induce the production of GM-CSF in cells present in the airway wall and thereby modulate the survival of neutrophils. The secondary aim was to determine whether GM-CSF is involved in accumulation of neutrophils in the airways caused by IL-17 and TNF-a.
Methods

In vitro experiments
Transformed human bronchial epithelial (16HBE14 0-(16HBE)) cells [26] were kindly donated by D.C. Gruenert (Gene Therapy Center, Cardiovascular Research Institute, Dept of Laboratory Medicine, University of California, CA, USA) and were used because of their ability to respond to inflammatory stimuli in a similar manner to primary human bronchial epithelial cells [27] . As an example of venous endothelial cells, human umbilical vein endothelial cells (HUVEC; Clonetics, San Diego, CA, USA) were used [28, 29] .
Cell culture conditions. 16HBE cells were grown in MEM Eagle-Eagle medium (GIBCO BRL, Life technology, Gaithesburg, MD, USA) with foetal calf serum (FCS; Sigma, St Louis, MO, USA) (10%), L-glutamine (2 mM), penicillin/streptomycin (100 U?mL -1 and 100 mg?mL ; Sigma) on collagen (bovine, type I; BD Biosciences, Bedford, MA, USA) and fibronectin (human; BD Biosciences) coated dishes [30] . HUVEC cells were grown in endothelial cell basal medium (Clonetics), supplemented with FCS (6%), hydrocortisone (1 mg?mL -1 ; Sigma), recombinant human epidermal growth factor (0.01 mg?mL -1 ), gentamicin (25 mg?mL ). All cells were grown to confluence in six-well plastic plates (BD Biosciences). At 18 h prior to the experiments, the concentration of FCS was reduced to 1% in 16HBE and to 2% in HUVEC cells to minimise the basal (inherent) cytokine release. Before addition of the stimulus, the cells were washed twice with phosphate-buffered saline (PBS; Sigma) and placed in fresh medium with 1% (16HBE) or 2% (HUVEC) FCS. PBS supplemented with 0.1% bovine serum albumin (BSA; Sigma) was used to deliver hIL-17 and hTNF-a and was also used as a vehicle.
Granulocyte macrophage-colony stimulating factor protein levels. Conditioned media were removed from cells and frozen at the end of each experiment. Thawed samples were centrifuged (1,7006g for 10 min) to pellet cells and cell debris. The supernatants were diluted and analysed using a high-sensitivity enzyme-linked immunosorbent assay (ELISA) for human GM-CSF (R&D Systems, Abingdon, UK).
Expression of mRNA for human granulocyte macrophagecolony stimulating factor. 16HBE cells were grown to confluence in six-well plates and treated with hIL-17, hTNF-a, the combination of hIL-17 and hTNF-a or vehicle. After 6 h the cells were harvested by scraping, washed with PBS and then suspended in ribonucleic acid (RNA) STAT-60 (TEL-TEST "B" INC., Friedswood, TX, USA). Total RNA was isolated and analysed using reverse transcriptase polymerase chain reaction (RT-PCR), as previously described [25, 31] , using simultaneous amplification of b-actin as an internal standard. Results were expressed as a ratio calculated from the volume of the amplified GM-CSF messenger (m)RNA product divided by the volume of the amplified housekeeping (b-actin) mRNA.
Neutrophil survival. Neutrophils were isolated from peripheral blood of healthy adult volunteers. Whole blood was sedimented in the presence of 4.5% Dextran T500 solution (Amersham-Pharmacia) for 1 h to remove red blood cells, monocytes and lymphocytes [32] . The residual erythrocytes were lysed in distilled water containing 0.8% NH 4 Cl and 0.1% KHCO 3 , and the remaining neutrophils were washed twice with Hanks balanced salt solution (Clonetics). Finally, the neutrophils were suspended in incubation medium (see below). This fraction contained (mean (SD)) 92% (1.2) neutrophils (n=4) with a viability ofw95%. To establish the indirect effect of IL-17 and TNF-a on neutrophil survival, the neutrophils (final concentration 3610 6 ?mL
) were suspended in conditioned media from 16HBE cells treated either with hIL-17, hTNF-a, the combination of hIL-17 and hTNF-a with and without anti-GM-CSF antibody, or vehicle and incubated at 37uC for a total of 96 h. To establish the direct effect of IL-17 on neutrophil survival the freshly prepared neutrophils (36106?mL -1 ) were incubated in nonconditioned MEM Eagle-Eagle medium with FCS (1%), L-glutamine (2 mM) and penicillin/streptomycin (100 U?mL -1 and 100 mg?mL
, respectively) containing 100 ng? mL -1 of IL-17. PBS with 0.1% of BSA (corresponds to the BSA concentration in PBS solution used as the delivery solution for the cytokines) was used as a negative control and GM-CSF (300 pg?mL -1 ) as a positive control. Survival of neutrophils was assessed at every 24-h interval using trypan blue exclusion [33] .
In vivo experiments
Pathogen-free C57BL/6 mice (male, 6-8 weeks old; B&K Universal AB, Stockholm, Sweden) were used under conditions approved by the Animal Ethics Committee in Gothenburg, Sweden (DNo. 316/98).
Intranasal treatment. The mice were transiently anaesthetised using carbon dioxide (CO 2 ; AGA Gas AB, Gothenburg, Sweden) and 50 ml of cytokine solution (dissolved in PBS solution containing 0.1% of BSA) was administered intranasally (i.n.). As a vehicle, 0.1% of BSA in PBS (50 ml) was used. The concentrations of mIL-17 and mTNF-a were chosen based on previous experiments in which 3 pg of mIL-17 and 0.01 mg of mTNF-a produced near-maximal effects in terms of neutrophil recruitment (data not shown).
Systemic blockade of granulocyte macrophage-colony stimulating factor. The mice were transiently anaesthetised using CO 2 gas and a specific monoclonal anti-mGM-CSF antibody (R&D Systems) that was administered intraperitoneally (i.p.) (100 mg in 0.1 mL PBS) 24 h prior to i.n. treatment. An isotype antibody (rat immunoglobulin (Ig)G2a; BD Biosciences) was administered i.p. (100 mg in 0.1 mL PBS) as a control.
Bronchoalveolar lavage. The mice were anaesthetised i.p. with a mixture of xylazin (130 mg?kg -1 ) and ketamine (670 mg?kg -1 ) (Apoteksbolaget, Gothenburg, Sweden) 6 h after intranasal treatment with cytokines or vehicle. Thereafter, tracheotomy was performed and bronchoalveolar lavage (BAL) was conducted (two times 0.25 mL of PBS) via a tracheal cannula. The recovered BAL suspension was pooled and kept on ice until centrifugation (at 1006g, 10 min, 4uC, using model 5403; Eppendorf-Netheler, Hamburg, Germany). The total number (i.e. concentration) of cells was determined using resuspended cell pellets from BAL suspension.
Neutrophil counts in bronchoalveolar lavage. Neutrophil counts were performed on cytospin slides prepared from BAL fluid (Cytospin 3; Shandon Life Science, Astmor, UK), using May-Grunwald-Giemsa staining. All slides were evaluated in a light microscope (Zeiss Axioplan 2; Carl Zeiss AG, Jena, Germany) at 61,000 magnification. The percentage and total number of neutrophils were calculated based on differential counts of 400 cells per sample.
Statistical analysis
Descriptive statistics are presented as median and range in text and as median plus single observations in figures. Only nonparametric methods were used for statistical analysis. Spearman rank correlation was used for correlation analysis of data. Wilcoxon9s signed-rank test was used for single paired comparisons and Kruskal Wallis test followed by Mann-Whitney U-test for comparisons between multiple independent groups. The number of independent experiments for each treatment group is referred to as n.
Results
In vitro experiments
Effect of IL-17 on granulocyte macrophage-colony stimulating factor protein release. In the concentration range 1-1,000 ng?
, hIL-17 increased the hGM-CSF concentration in conditioned medium from 16HBE cells in a concentrationdependent fashion ( fig. 1 ). Co-incubation with an anti-hIL-17 antibody blocked this increase in hGM-CSF ( fig. 1) , as did pretreatment with hydrocortisone ( fig. 2) . hIL-17 (1-1,000 ng?mL -1 ) also increased hGM-CSF in a concentration-dependent fashion in HUVEC cells (n=2, data not shown).
In the time range 2-18 h, hIL-17 (100 ng?mL ) exerted a synergistic effect on the release of hGM-CSF ( fig. 2 ). This synergistic release of hGM-CSF was more pronounced than that observed after treatment with a maximum effective concentration (100 ng?mL ), compared with vehicle (V) on human granulocyte macrophage-colony stimulating factor (hGM-CSF) protein concentration in conditioned medium from 16HBE cells. Co-treatment with hIL-17 and hTNF-a produced a synergistic effect on the concentration of hGM-CSF (Wilcoxon signed-rank pv0.05, compared with the sum of IL-17 alone or hTNF-a alone, n=6). The concentration of hGM-CSF after this co-treatment was also significantly higher (Wilcoxon signed-rank pv0.05, n=6) than after treatment with a maximum effective concentration of hTNF-a alone. 
alone (fig. 2). hIL-17 (100 ng?mL -1 ) also increased hGM-CSF in a time-dependent fashion in 16HBE cells (n=2, data not shown).
Effect of IL-17 on granulocyte macrophage-colony stimulating factor mRNA levels. Stimulation of a 6-h duration of 16HBE cells with hIL-17 (100 ng?mL ) or vehicle. The survival of neutrophils was evaluated every 24 h by calculating the area under the curve (AUC; number of living neutrophils6h) over 48-96 h and the differences were also compared at every single time point, which were most pronounced at 72 h ( fig. 6 ). Over 48-96 h, conditioned medium from 16HBE cells co-stimulated with hIL-17 plus hTNF-a prolonged the survival of human neutrophils (AUC 2,299.6 (1,774.0-2,433.6)), compared with neutrophils exposed to conditioned cell medium from 16HBE cells stimulated with hTNF-a alone (AUC 1,765.6 (1,505.5-2,322.0)) (pv0.05, n=6). Pretreatment of this conditioned medium with a neutralising anti-hGM-CSF antibody (10 pg?mL -1 added simultaneously with cytokines) blocked the prolonging effect on neutrophil survival (AUC 1,527.7 (1,433.9-1,922.2)) (pv0.05, n=6). However, as was also shown at 72 h ( fig. 6 ), neither conditioned medium from 16HBE cells co-stimulated with hIL-17 plus hTNF-a nor the one stimulated with either hIL-17 alone (AUC 1,855.0 (1,611.0-2,581.6)) or hTNF-a alone (AUC 1,765.6 (1,505.5-2,322.0)) prolonged neutrophil survival significantly compared with conditioned medium from vehicle-stimulated 16HBE cells (AUC 1,720.5 (1,594.9-2,133.7)) (pw0.05, n=6). ), the combination of hIL-17 plus hTNF-a or the combination of hIL-17 plus hTNF-a plus a neutralising antihuman granulocyte macrophage-colony stimulating factor (hGM-CSF) antibody (ab) were tested. hIL-17zhTNF-a medium displayed a significantly higher neutrophil survival than hTNF-a medium and hIL-17zhTNF-azGM-CSF ab medium, respectively. Data are presented as median (vertical bold line) plus individual values. *: Wilcoxon signed-rank pv0.05, n=6. substantial direct effect on neutrophil survival as compared with vehicle (AUC 1,254.4 (868.1-1,284.7)) (pw0.05, n=3).
In vivo experiments
Effect on neutrophil recruitment in vivo. i.n. stimulation with mIL-17 markedly increased the number of neutrophils in BAL fluid and this accumulation of neutrophils was additively potentiated by mTNF-a (fig. 7a) . Pretreatment with the antimGM-CSF antibody i.p. abolished the increase in BAL neutrophils caused by stimulation with IL-17 plus TNF-a i.n. (fig. 7b) .
Discussion
There is clear experimental in vivo evidence supporting a role for activated T-lymphocytes in the accumulation of neutrophils in the airways [34, 35] . There is also evidence that IL-17 may constitute a mechanistic link between T-lymphocytes and neutrophils; IL-17 is produced by T-lymphocytes [18] and causes selective accumulation of neutrophils but not other inflammatory cells in the airways [25] . The current study provides additional evidence supporting the hypothesis that IL-17 constitutes a link between T-lymphocytes and neutrophils by demonstrating that IL-17, with and without costimulation with TNF-a, causes accumulation of neutrophils depending upon GM-CSF in the airways.
Specifically, the current authors have shown that hIL-17 stimulates release of GM-CSF protein in models of human bronchial epithelial and venous endothelial cells in vitro, two potential effector cells in the local control of neutrophil recruitment in the airways. This IL-17-induced GM-CSF release appears to be both concentration-and time-dependent in the models of human bronchial epithelial and venous endothelial cells used. Furthermore, the effect of hIL-17 is probably protein specific, because it is attenuated by a neutralising antihIL-17 antibody in human bronchial epithelial cells. Previous data on receptor binding in fibroblasts suggests a low-affinity IL-17 receptor in other types of human cells [36] and the moderate effect of hIL-17 on GM-CSF release now observed in human bronchial epithelial cells, as well as the corresponding shallow concentration/response curve, also suggests a lowaffinity receptor in these cells. In line with these findings, stimulation of human bronchial epithelial cells with hIL-17 alone increases mRNA for GM-CSF with the same order of magnitude as TNF-a, suggesting an induced de novo synthesis of GM-CSF. The inhibitory effect exerted by the glucocorticoid hydrocortisone on hIL-17-induced GM-CSF release is probably due to inhibition of the transcription factor nuclear factor (NF)-kB [37] , a factor that is known to be important in IL-17-induced cytokine release [21, 38] .
Interestingly, the present authors demonstrate that costimulation with hIL-17 and hTNF-a potentiates the release of GM-CSF protein in human bronchial epithelial cells in vitro. They also demonstrate that this production of GM-CSF is functionally significant; conditioned medium from human bronchial epithelial cells co-stimulated with hIL-17 plus hTNF-a prolongs the survival of human neutrophils in vitro and this prolonging effect on survival is inhibited by a neutralising anti-hGM-CSF antibody. Finally, the authors demonstrate that hIL-17 per se exerts no direct effect on the survival of human neutrophils in vitro, thereby suggesting an indirect effect exerted by IL-17 on the accumulation of neutrophils.
The current authors show that mIL-17 potentiates mTNFa-induced accumulation of neutrophils in mouse airways, thereby providing functional evidence for the relevance of IL-17 in vivo. In addition, the authors provide evidence that this functionally significant effect of mIL-17 and mTNF-a is dependent upon mGM-CSF. It appears likely that the referred GM-CSF exerts its role by increasing the recruitment of neutrophils into the airways; this latter type of effect is likely to rely on an increased release of new neutrophils from the bone marrow [12] , as well as on an increased adhesion to and migration through the vascular walls in airway tissue [19] [20] [21] [22] . The main reason for this conclusion is that the antimGM-CSF antibody was administered 24 h prior to intranasal stimulation with mIL-17 and mTNF-a, and BAL was harvested 6 h later, giving a total maximum of 30 h for the antibody to act. This limited time frame makes it less likely that the in vivo effect of the anti-mGM-CSF antibody was due to an altered neutrophil survival, which would require several days of treatment with an anti-mGM-CSF antibody to be demonstrated. However, the mechanistic details of these events remain to be clarified through studies of bone marrow, blood and BAL fluid over time.
The current authors believe that the demonstrated potentiating effect of IL-17 and TNF-a on the accumulation of neutrophils in the airways has implications for human disease. Increased levels of TNF-a can be detected in several types of inflammatory airway diseases, including bronchial asthma and COPD [39, 40] . As demonstrated in vitro, TNF-a can induce neutrophil recruitment by increasing the release of IL-6, IL-8 and GM-CSF [41] . In view of recent evidence that IL-17 itself may be present in human airways during severe inflammation [16, 17] , it is possible that IL-17 interacts with TNF-a and, through induced GM-CSF release, contributes to the accumulation of neutrophils.
In conclusion, this experimental study indicates that glucocorticoid-sensitive de novo production of granulocyte macrophage-colony stimulating factor from bronchial epithelial cells is involved in the accumulation of neutrophils in the airways caused by interleukin-17 and tumour necrosis factora. In addition, venous endothelial cells may also respond to interleukin-17 by releasing granulocyte macrophage-colony stimulating factor. It appears feasible that this granulocyte macrophage-colony stimulating factor exerts its functionally significant effects in vivo on both the recruitment and survival of neutrophils in the airways.
